| 1.4 0.25 (21.74%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.69 |
1-year : | 1.97 |
| Resists | First : | 1.45 |
Second : | 1.69 |
| Pivot price | 1.14 |
|||
| Supports | First : | 1.12 |
Second : | 0.92 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.14 |
| MA(100) : | 2.16  |
MA(250) : | 2.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 65.8 |
D(3) : | 50.3 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 8.81 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIXC ] has closed above the upper band by 25.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 67.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.46 |
| Low: | 1.13 - 1.13 | 1.13 - 1.14 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.
Tue, 17 Mar 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Mon, 16 Mar 2026
AIxCrypto explores building the pipes for a world of autonomous AI agents - Stock Titan
Fri, 27 Feb 2026
AIxCrypto launches Season 2 of AIxC Hub, refocuses on RWA and Embodied AI - TradingView
Thu, 26 Feb 2026
Inside AIxCrypto’s 4.8M-wallet hub and its new arena where AI agents compete - Stock Titan
Sun, 22 Feb 2026
AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Hub Season 2 Launch, and Social Growth Momentum - Sahm
Fri, 20 Feb 2026
AIxCrypto stock rises after real estate partnership deal - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 18.4 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 98 (K) |
| Shares Short P.Month | 94 (K) |
| EPS | 2.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0.48 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|